{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:55:15Z","timestamp":1768006515208,"version":"3.49.0"},"reference-count":58,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,12,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Myelofibrosis (MF), either primary or arising from previous polycythemia vera (PV) or essential thrombocythemia (ET), is the worst among the chronic myeloproliferative neoplasms in terms of survival and quality of life. Patients with MF have to face several clinical issues that, because of the poor effectiveness of medical therapy, surgery or radiotherapy, represent largely unmet clinical needs. Powerful risk stratification systems, applicable either at diagnosis using the International Prognostic Scoring System (IPSS) or during the variable course of illness using the Dynamic International Prognostic Scoring System (DIPSS) and DIPSS Plus, allow recognition of categories of patients with survival times ranging from decades to &lt; 2 years. These scores are especially important for therapeutic decisions that include allogeneic stem cell transplantation (allogeneic SCT), the only curative approach that still carries a nonnegligible risk of morbidity and mortality even with newest reduced intensity conditioning (RIC) regimens. Discovery of JAK2V617F mutation prompted the development of clinical trials using JAK2 inhibitors; these agents overall have resulted in meaningful symptomatic improvement and reduction of splenomegaly that were otherwise not achievable with conventional therapy. Intriguing differences in the efficacy and tolerability of JAK2 inhibitors are being recognized, which could lead to a nonoverlapping spectrum of activity\/safety. Other agents that do not directly target JAK2 and have shown symptomatic efficacy in MF are represented by inhibitors of the mammalian target of rapamycin (mTOR) and histone deacetylases (HDACs). Pomalidomide appears to be particularly active against MF-associated anemia. However, because these agents are all poorly effective in reducing the burden of mutated cells, further advancements are needed to move from enhancing our ability to palliate the disease to arriving at an actual cure for MF.<\/jats:p>","DOI":"10.1182\/asheducation-2011.1.222","type":"journal-article","created":{"date-parts":[[2011,12,7]],"date-time":"2011-12-07T20:33:13Z","timestamp":1323289993000},"page":"222-230","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":37,"title":["Management of Myelofibrosis"],"prefix":"10.1182","volume":"2011","author":[{"given":"Alessandro M.","family":"Vannucchi","sequence":"first","affiliation":[{"name":"Section of Hematology, University of Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"4","key":"2019111717423802200_B1","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","article-title":"Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel","volume":"110","author":"Tefferi","year":"2007","journal-title":"Blood"},{"issue":"2","key":"2019111717423802200_B2","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","article-title":"Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment","volume":"22","author":"Barosi","year":"2008","journal-title":"Leukemia"},{"issue":"6","key":"2019111717423802200_B3","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2010.69","article-title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"issue":"1","key":"2019111717423802200_B4","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2007-05-091850","article-title":"Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes","volume":"111","author":"Wilkins","year":"2008","journal-title":"Blood"},{"issue":"18","key":"2019111717423802200_B5","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.2008.20.3174","article-title":"Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy","volume":"27","author":"Campbell","year":"2009","journal-title":"J Clin Oncol"},{"issue":"23","key":"2019111717423802200_B6","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and risk of leukemic transformation in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study of 1,104 patients","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111717423802200_B7","doi-asserted-by":"crossref","first-page":"5710","DOI":"10.1182\/blood-2010-07-293761","article-title":"Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification","volume":"117","author":"Thiele","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2019111717423802200_B8","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.leukres.2006.12.002","article-title":"Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT)","volume":"31","author":"Mesa","year":"2007","journal-title":"Leuk Res"},{"issue":"13","key":"2019111717423802200_B9","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"9","key":"2019111717423802200_B10","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2019111717423802200_B11","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS Plus: A refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111717423802200_B12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/ajh.21574","article-title":"Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis\u2013prognostic relevance is independent of IPSS or karyotype","volume":"85","author":"Tefferi","year":"2010","journal-title":"Am J Hematol"},{"issue":"2","key":"2019111717423802200_B13","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1600-0609.2009.01373.x","article-title":"Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival","volume":"84","author":"Patnaik","year":"2010","journal-title":"Eur J Haematol"},{"issue":"1","key":"2019111717423802200_B14","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/leu.2010.234","article-title":"Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients","volume":"25","author":"Caramazza","year":"2011","journal-title":"Leukemia"},{"issue":"4","key":"2019111717423802200_B15","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.leu.2405097","article-title":"Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"issue":"8","key":"2019111717423802200_B16","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1182\/blood-2009-04-216044","article-title":"Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele","volume":"114","author":"Guglielmelli","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2019111717423802200_B17","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/leu.2009.225","article-title":"JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46\/1 haplotype is associated with inferior survival","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"issue":"10","key":"2019111717423802200_B18","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111717423802200_B19","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.1182\/blood-2010-11-320002","article-title":"Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival","volume":"117","author":"Vaidya","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2019111717423802200_B20","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"18","key":"2019111717423802200_B21","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1182\/blood-2009-12-260588","article-title":"Impact of JAK2V617F-mutation status, allele burden and clearance after allogeneic stem cell transplantation for myelofibrosis","volume":"116","author":"Alchalby","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2019111717423802200_B22","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/bmt.2009.188","article-title":"Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type","volume":"45","author":"Bacigalupo","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2019111717423802200_B23","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1365-2141.2008.07010.x","article-title":"Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation","volume":"141","author":"Ciurea","year":"2008","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111717423802200_B24","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/ajh.21342","article-title":"Survival in young patients with intermediate- \/ high-risk myelofibrosis: estimates derived from databases for non transplant patients","volume":"84","author":"Siragusa","year":"2009","journal-title":"Am J Hematol"},{"issue":"33","key":"2019111717423802200_B25","doi-asserted-by":"crossref","first-page":"5587","DOI":"10.1200\/JCO.2009.22.8833","article-title":"Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera\/essential thrombocythemia myelofibrosis","volume":"27","author":"Tam","year":"2009","journal-title":"J Clin Oncol"},{"issue":"13","key":"2019111717423802200_B26","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1182\/blood-2010-11-315614","article-title":"How I treat myelofibrosis","volume":"117","author":"Tefferi","year":"2011","journal-title":"Blood"},{"issue":"10","key":"2019111717423802200_B27","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1517\/14656566.2011.568939","article-title":"Therapeutic approaches in myelofibrosis","volume":"12","author":"Barosi","year":"2011","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"2019111717423802200_B28","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1365-2141.2006.06142.x","article-title":"Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia","volume":"134","author":"Cervantes","year":"2006","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111717423802200_B29","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/ajh.21892","article-title":"International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens","volume":"86","author":"Thapaliya","year":"2011","journal-title":"Am J Hematol"},{"issue":"8","key":"2019111717423802200_B30","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1038\/sj.leu.2404711","article-title":"Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions","volume":"21","author":"Tefferi","year":"2007","journal-title":"Leukemia"},{"issue":"22","key":"2019111717423802200_B31","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1182\/blood-2010-05-287417","article-title":"Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903","volume":"116","author":"Mesa","year":"2010","journal-title":"Blood"},{"key":"2019111717423802200_B32","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1200\/JCO.2009.22.6548","article-title":"Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis","volume":"27","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019111717423802200_B33","doi-asserted-by":"crossref","first-page":"5394","DOI":"10.1182\/blood-2009-02-195974","article-title":"How I treat symptomatic splenomegaly in patients with myelofibrosis","volume":"113","author":"Mesa","year":"2009","journal-title":"Blood"},{"issue":"15","key":"2019111717423802200_B34","first-page":"LBA6501A","article-title":"Results of a randomized study of the JAK inhibitor INC424 compared with best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PETMF) [Abstract]","volume":"29","author":"Harrison","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111717423802200_B35","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1600-0609.2004.00370.x","article-title":"Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia","volume":"74","author":"Faoro","year":"2005","journal-title":"Eur J Haematol"},{"issue":"4","key":"2019111717423802200_B36","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","article-title":"Thrombosis in primary myelofibrosis: incidence and risk factors","volume":"115","author":"Barbui","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2019111717423802200_B37","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s00277-010-1019-9","article-title":"Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients","volume":"89","author":"Mart\u00ednez-Trillos","year":"2010","journal-title":"Ann Hematol"},{"issue":"1","key":"2019111717423802200_B38","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cncr.22365","article-title":"The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients","volume":"109","author":"Mesa","year":"2007","journal-title":"Cancer"},{"key":"2019111717423802200_B39","article-title":"Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement [published online ahead of print April 8, 2011]","author":"Mesa","journal-title":"Cancer"},{"issue":"24","key":"2019111717423802200_B40","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1182\/blood-2010-11-320069","article-title":"Recombinant interferon alpha may retard progression of early primary myelofibrosis: a preliminary report","volume":"117","author":"Silver","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2019111717423802200_B41","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3816\/CLML.2010.n.059","article-title":"Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis","volume":"10","author":"Parikh","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"20","key":"2019111717423802200_B42","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1182\/blood-2010-04-279125","article-title":"Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon {alpha} specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells","volume":"116","author":"Lu","year":"2010","journal-title":"Blood"},{"issue":"10","key":"2019111717423802200_B43","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1172\/JCI42442","article-title":"HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans","volume":"120","author":"Marubayashi","year":"2010","journal-title":"J Clin Invest"},{"issue":"27","key":"2019111717423802200_B44","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2008.21.7356","article-title":"Pomalidomide is active in the treatment of anemia associated with myelofibrosis","volume":"27","author":"Tefferi","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111717423802200_B45","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/leu.2010.254","article-title":"A phase-2 trial of low-dose pomalidomide in myelofibrosis","volume":"25","author":"Begna","year":"2011","journal-title":"Leukemia"},{"issue":"8","key":"2019111717423802200_B46","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1182\/blood-2011-01-330563","article-title":"Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1\/2 study in patients with myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"key":"2019111717423802200_B47","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1038\/bcj.2011.4","article-title":"Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium [Abstract]","volume":"1","author":"Tefferi","year":"2011","journal-title":"Blood Cancer J"},{"key":"2019111717423802200_B48","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1111\/j.1582-4934.2009.00827.x","article-title":"Epigenetic Therapy in Myeloproliferative Neoplasms: Evidence and Perspectives","volume":"13","author":"Vannucchi","year":"2009","journal-title":"J Cell Mol Med"},{"key":"2019111717423802200_B49","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/leu.2008.136","article-title":"5-Azacitidine has limited therapeutic activity in myelofibrosis","volume":"23","author":"Mesa","year":"2009","journal-title":"Leukemia"},{"key":"2019111717423802200_B50","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2141.2008.07541.x","article-title":"Decitabine is an effective treatment of idiopathic myelofibrosis","volume":"145","author":"Danilov","year":"2009","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111717423802200_B51","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1365-2141.2010.08266.x","article-title":"A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms","volume":"150","author":"Rambaldi","year":"2010","journal-title":"Br J Haematol"},{"issue":"21","key":"2019111717423802200_B52","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1182\/blood.V116.21.630.630","article-title":"A phase II trial of panobinostat, an orally available deacetylase inhibitor (DACi), in patients with primary myelofibrosis (PMF), post essential thrombocythemia (ET), and post polycythemia vera (PV) myelofibrosis [Abstract]","volume":"116","author":"DeAngelo","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2019111717423802200_B53","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"issue":"15","key":"2019111717423802200_B54","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1200\/jco.2011.29.15_suppl.6500","article-title":"Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1\/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF) [Abstract]","volume":"29","author":"Verstovsek","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111717423802200_B55","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","article-title":"Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis","volume":"29","author":"Pardanani","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111717423802200_B56","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1182\/blood-2009-10-246363","article-title":"Phase II study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post polycythemia vera\/essential thrombocythemia myelofibrosis","volume":"115","author":"Santos","year":"2010","journal-title":"Blood"},{"key":"2019111717423802200_B57","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1182\/blood.V116.21.460.460","article-title":"A Phase I\/II study of CYT387, an oral JAK-1\/2 inhibitor, in myelofibrosis: significant response rates in anemia, splenomegaly, and constitutional symptoms [Abstract]","volume":"116","author":"Pardanani","year":"2010","journal-title":"Blood"},{"issue":"15","key":"2019111717423802200_B58","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.1200\/jco.2011.29.15_suppl.6515","article-title":"Phase II study of SB1518, an orally available novel JAK2 inhibitor, in patients with myelofibrosis [Abstract]","volume":"29","author":"Deeg","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2011\/1\/222\/1493859\/bep00111000222.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2011\/1\/222\/1493859\/bep00111000222.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T13:24:05Z","timestamp":1713187445000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2011\/1\/222\/96974\/Management-of-Myelofibrosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,10]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2011.1.222","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,10]]}}}